Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;4(11):1538-1543.
doi: 10.1038/s43587-024-00732-x. Epub 2024 Oct 25.

Informant characteristics influence Clinical Dementia Rating Sum of Boxes scores-based staging of Alzheimer's disease

Affiliations

Informant characteristics influence Clinical Dementia Rating Sum of Boxes scores-based staging of Alzheimer's disease

Juan-Camilo Vargas-Gonzalez et al. Nat Aging. 2024 Nov.

Abstract

The Clinical Dementia Rating Sum of Boxes (CDR-SB) is a staging scale for Alzheimer's disease (AD)1 and is commonly used as an outcome in clinical trials2. It relies on information provided by the patient and an informant3. The CDR-SB should reflect only the patient's disease severity. However, we explored whether informant characteristics were associated with CDR-SB scores because that association might introduce bias in Alzheimer's disease research. We found that the CDR-SB was 0.20 higher when informants were female, 0.39 higher when the informant was a patient's child and 0.18 lower if the relationship was other than spouse or children. Regarding the frequency of contact, CDR-SB scores were 0.38 higher when contact was at least once a week, 0.65 higher when daily and 0.57 higher when living with the patient. Our analysis results suggest that informant characteristics can modify the CDR-SB scores and might introduce bias into Alzheimer's disease trials and research.

PubMed Disclaimer

Conflict of interest statement

Competing interests J.-C.V.-G. declares no competing interests. A.S.C. is the cofounder and pro bono chief executive officer of the Women’s Brain Project, and the pro bono Euresearch vice president. L.C.-A. is the scientific project manager of the Women’s Brain Project. M.T.F. is the cofounder of the Women’s Brain Project. In the past 2 years, she has received consulting and speaking fees from Roche, Eli Lilly and Lundbeck unrelated to this project. She is currently clinical development lead of Syntropic Medical. M.C.T. has funding from National Institute of Aging, Weston Brain Foundation and Tanenbaum Institute of Science in Sport, and has consulted for Eisai and Eli Lilly.

Update of

Similar articles

Cited by

References

    1. Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993). - DOI - PubMed
    1. Cedarbaum, J. M. et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimers Dement. 9, S45–S55 (2013). - DOI - PubMed
    1. Coley, N. et al. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials. Alzheimers Dement. 7, 602–610.e2 (2011). - DOI - PubMed
    1. Knopman, D. S. et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 131, 2957–2968 (2008). - DOI - PubMed - PMC
    1. O’Bryant, S. E. et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s Research Consortium study. Arch. Neurol. 65, 1091–1095 (2008). - DOI - PubMed - PMC

LinkOut - more resources